Citius Pharmaceuticals (CTXR) Stock Statistics & Valuation Metrics

Citius Pharmaceuticals has a market cap or net worth of $18.48M. The enterprise value is $4.05M.

Citius Pharmaceuticals has 27,452,570 shares outstanding. The number of shares has decreased by -2.65% in one year.

Citius Pharmaceuticals’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -44.23%.

The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is 0.00845.

In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -37.43M in profits. Earnings per share was -3.38.

In the last 12 months, operating cash flow was -31.60M and capital expenditures 4.00, giving a free cash flow of -31.60M billion.

Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Citius Pharmaceuticals upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).

Citius Pharmaceuticals as a current ratio of 0.62, with Debt / Equity ratio of 1.31%

In the past 12 months, Citius Pharmaceuticals has paid 1.06M in taxes.

Citius Pharmaceuticals EV to EBITDA ratio is -0.30, with an EV/FCF ratio of -0.42.

Citius Pharmaceuticals has $4.59M in cash and marketable securities with $808.16K in debt, giving a net cash position of $3.78M billion.

Gross margin is 37.36%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Citius Pharmaceuticals is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy